By sharing her own experiences and helping athletes see their value, Anne has truly become the ultimate “coach.” When she ...

I had a symptom of colon cancer and family history, so I got a colonoscopy. It was expensive, and insurance was a nightmare, ...

When Brenda Harbin’s husband, Joe, was preparing to take a Cologuard screening test for colon cancer in late April 2017, she ...

Other colon cancer screening tests currently under development are at-home blood sample tests. Their low level of accuracy means they are currently not recommended for use in place of FOBT, FIT ...

The company is also making headway with its blood-based colon cancer screening test, with top-line results from the pivotal BLUE-C study expected by mid-2025. Factors Weighing on EXAS Stock ...

In Cannes last week, creative leaders from Area 23, The Bloc, Eversana and MMC joined MM+M in the Palais basement to walk the ...

BofA analysts review the promise and limits of AI in precision medicine, highlighting key players like Tempus, Guardant, and ...

Cologuard is an at-home cancer-screening product. Developers say it detects 94 percent of colon cancer, the same percentage as a colonoscopy.

The ruling ensures continued coverage, without patient cost-sharing, of services including BRCA testing and colorectal cancer screening, potentially impacting firms like Exact Sciences.

Of the 30 companies included in the list, 24 firms saw their stock prices rise, four saw their share prices decline, and two saw their stock prices remain flat.